{"id":2878,"date":"2018-11-06T12:05:36","date_gmt":"2018-11-06T12:05:36","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=2878"},"modified":"2018-11-06T12:05:36","modified_gmt":"2018-11-06T12:05:36","slug":"enyo-pharma-annonce-le-succes-de-sa-phase-ib-avec-son-agoniste-de-fxr-eyp001-et-le-debut-de-ses-etudes-de-phase-ii-dans-deux-indications-nash-et-hbv","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-le-succes-de-sa-phase-ib-avec-son-agoniste-de-fxr-eyp001-et-le-debut-de-ses-etudes-de-phase-ii-dans-deux-indications-nash-et-hbv\/","title":{"rendered":"Â鶹Æƽâ°æ annonce le succ\u00e8s de sa phase Ib avec son agoniste de FXR EYP001 et le d\u00e9but de ses \u00e9tudes de phase II dans deux indications, NASH et HBV"},"content":{"rendered":"<p>Lyon, le 06 novembre 2018 \u2013 Â鶹Æƽâ°æ, soci\u00e9t\u00e9 biopharmaceutique d\u00e9veloppant de nouveaux candidats m\u00e9dicaments innovants imitant les strat\u00e9gies des virus pour moduler les fonctions cellulaires de l\u2019h\u00f4te, annonce aujourd\u2019hui la r\u00e9ussite de ses \u00e9tudes cliniques de phase Ib \u00e9valuant la pharmacocin\u00e9tique et les pharmacodynamiques de son compos\u00e9 agoniste de FXR EYP001 chez des patients atteints du virus de l\u2019h\u00e9patite B chronique. L\u2019entreprise met en \u00e9vidence que EYP001 a bien \u00e9t\u00e9 tol\u00e9r\u00e9 par les patients et a induit un engagement prolong\u00e9 de la cible FXR. Â鶹Æƽâ°æ va maintenant initier les deux essais cliniques de Phase II d\u2019EYP001 \u00e0 la fois dans NASH et CHBV. <\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2018\/11\/ENYO-Pharma-Press-Release-Phase-Ib-French.pdf\" target=\"_blank\" rel=\"noopener\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiquer complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, le 06 novembre 2018 \u2013 Â鶹Æƽâ°æ, soci\u00e9t\u00e9 biopharmaceutique d\u00e9veloppant de nouveaux candidats m\u00e9dicaments innovants imitant les strat\u00e9gies des virus pour moduler les fonctions cellulaires de l\u2019h\u00f4te, annonce aujourd\u2019hui la r\u00e9ussite de ses \u00e9tudes cliniques de phase Ib \u00e9valuant la pharmacocin\u00e9tique et les pharmacodynamiques de son compos\u00e9 agoniste de FXR EYP001 chez des patients atteints du virus de l\u2019h\u00e9patite B chronique. L\u2019entreprise met en \u00e9vidence que EYP001 a bien \u00e9t\u00e9 tol\u00e9r\u00e9 par les patients et a induit un engagement prolong\u00e9 de la cible FXR.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-le-succes-de-sa-phase-ib-avec-son-agoniste-de-fxr-eyp001-et-le-debut-de-ses-etudes-de-phase-ii-dans-deux-indications-nash-et-hbv\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-2878","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, le 06 novembre 2018 \u2013 Â鶹Æƽâ°æ, soci\u00e9t\u00e9 biopharmaceutique d\u00e9veloppant de nouveaux candidats m\u00e9dicaments innovants imitant les strat\u00e9gies des virus pour moduler les fonctions cellulaires de l\u2019h\u00f4te, annonce aujourd\u2019hui la r\u00e9ussite de ses \u00e9tudes cliniques de phase Ib \u00e9valuant la pharmacocin\u00e9tique et les pharmacodynamiques de son compos\u00e9 agoniste de FXR EYP001 chez des patients&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=2878"}],"version-history":[{"count":3,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2878\/revisions"}],"predecessor-version":[{"id":2889,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/2878\/revisions\/2889"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=2878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=2878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=2878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}